ArticleFood science & nutrition2025
Chrysoeriol Chemosensitized Renal Cell Carcinoma (RCC) Cell Lines to Trigger TRAIL Induced Apoptosis In Vitro by Up-Regulating Pro-Apoptotic and Down-Regulating Anti-Apoptotic Genetic Factors.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal carcinoma is a lethal cancer, researched by several studies to get insights into the molecular causes of disease, in order to come up with advanced therapeutic treatments. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), is an anticancer cytokine posing therapeutic effects to treat cancer. However, certain cancer types including renal cell carcinoma developed resistance towards TRAIL, hence limiting its usefulness in cancer treatment. Recently, synergistic approach has been emerged in clinical settings to sensitize cancer cells towards TRAIL treatment by combining with natural antioxidants and anti-inflammatory compounds for providing chemo-sensitizing effects. Hence, this study has used chemo-sensitizing effect of chrysoeriol for the very first time to sensitize renal carcinoma cell lines for treatment with TRAIL by synergistic treatment approach, in vitro. The effects of 20 μM chrysoeriol, 50 ng/mL TRIAL and their synergistic combination were investigated deeply by adopting different experimental strategies in vitro. Synergistic combination of 20 μM chrysoeriol/50 ng/mL TRIAL provided apoptosis of TRAIL resistant cell lines which was confirmed by increasing the expressions of caspases including caspase-3 and caspase-8 and caspase-9, increasing the expression of interleukins 10, while decreasing the expression of interleukins 6, triggering cellular apoptosis, inhibiting proteasome activity, lossing mitochondrial membrane potential and triggering cytchrome C release. Meanwhile, rise in death receptor 4 expression as well as up-regulation of pro-apoptotic and down-regulation of anti-apoptotic genes further provided evidence for chemo-sensitizing effect of chrysoeriol on TRAIL resistant renal carcinoma cells to trigger apoptosis. Hence, chrysoeriol could be employed in the anticancer drug development for therapeutic treatment of renal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.